Following were the notable penny stock buzzers in the previous session on high volume. Keep an eye on these stocks this week.
If you are interested in nanocap stocks here is one you should look into
Wearable Health Solutions (OTCMKTS:WHSI) is a manufacturer of next-generation, advanced technology personal medical alarms and safety alert devices. WHSI’s technology can provide a leading edge for the Company in our current cutting-edge technology-driven markets.
● Unique Opportunity
Only Publicly Traded Small-Cap Stock in the $7.4 Billion PERS Market
● Major Marketing Campaign Kickoff Imminent
WHSI is launching a worldwide marketing campaign to expand its international network of distributors. Production is underway for the company’s spots on the weekly ‘Worldwide Business With kathy ireland®” show.
Ireland’s Company Reaches Over 200+ Million Households broadcast on FOX Business Network, Bloomberg International Television and video streams on all major social media platforms.
● iMax 4G Release
WHSI’s iHelp MAX™ 4G device is reportedly launching this year. The device will do more than transmit an emergency alarm for the user. It will also send medical personnel vital signs, such as heart rate.
This next-generation release would be huge for WHSI stock.
● WHSI Up Listing
WHSI’s Mark Cayle recently commented after releasing its Form 10, “Once our Form 10 Registration Statement is effective, we will consider an up listing to a broader stock exchange which could expand our exposure to institutional investors, money managers, family office funds, broker dealers, and other investors which is an important milestone in our corporate progression,” he concluded
An uplisting would be a major catalytic event.
Hoth Therapeutics Inc. (NASDAQ:HOTH) was under heavy selling pressure in the previous session. The stock slumped 31.43% at $0.72 with over 16.50 million shares traded hands, compared to its average volume of 3.88 million shares.
The company announced acceptance to present the preclinical Alzheimer’s disease mouse model data of HT-ALZ at the Alzheimer’s Association International Conference taking place July 31 – August 4, 2022 in San Diego, California. The presentation will include results from cognitive and behavioral studies currently underway with HT-ALZ using an APP/PS1 mouse model.
Athersys Inc. (NASDAQ:ATHX) stock continued to trend lower on Tuesday. On Tuesday, the stock slid 31% to $0.59 with more than 15.25 million shares traded hands, compared to its average volume of 2.22 million shares. The Cleveland company said its Japanese partner has completed follow-up examinations of ischemic stroke patients who were treated with MultiStem.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) was one of the biggest losers on Tuesday. The stock tanked 31.33% to $1.14 with over 4.10 million shares traded hands, compared to its average volume of 1.27 million shares. The company provided a business update and reported its second half and full 2021 financial results.
“We are progressing preclinical development of AM-401 for treatment of KRAS-driven cancer as the first indication for our OligoPhore delivery platform with siRNAs,” stated Thomas Meyer, Altamira Therapeutics’ founder, Chairman and CEO. “In our legacy business, we are laying the foundations for long-term growth with our drug-free Bentrio nasal spray through partnering with international distributors, as well as advancing our AM-125 nasal spray for vertigo treatment towards important milestones this year.
Genocea Biosciences Inc. (NASDAQ:GNCA) stock was one of the notable active movers in previous trading session as the stock ended lower by 19% to $0.49 with over 5.17 million shares traded hands, compared to its average volume of 1.46 million shares.
The company says that the early results presented at American Association for Cancer Research (AACR) show anti-tumor activity despite the lower intensity regimens and heavily pretreated tumors. Stable disease was seen at the initial Day 57 scan in four of the five patients. While all patients had progressive disease (PD) at their Day 113 scan, three of the five experienced clear biologic changes after infusion.
Kintara Therapeutics Inc. (NASDAQ:KTRA) stock was one of the most active stock buzzers. The stock slid 31% to $0.3450 with over 6.24 million shares traded hands, compared to its average volume of 957k shares. The firm entered into definitive agreements with institutional investors for the purchase and sale of 16,226,416 shares of its common stock and warrants to purchase 16,226,416 shares of its common stock at a combined purchase price of $0.53 per share and related warrant.
